Raymond James & Associates Cognition Therapeutics Inc Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Cognition Therapeutics Inc stock. As of the latest transaction made, Raymond James & Associates holds 10,000 shares of CGTX stock, worth $5,800. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,000
Previous 10,000
-0.0%
Holding current value
$5,800
Previous $16,000
75.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding CGTX
# of Institutions
45Shares Held
6.58MCall Options Held
0Put Options Held
0-
Pathstone Family Office, LLC Englewood, NJ2.21MShares$1.28 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.24MShares$720,6810.0% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL500KShares$290,0000.0% of portfolio
-
Geode Capital Management, LLC Boston, MA324KShares$187,7120.0% of portfolio
-
Cm Management, LLC250KShares$145,0000.1% of portfolio
About COGNITION THERAPEUTICS INC
- Ticker CGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,710,700
- Market Cap $13.2M
- Description
- Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical tr...